Compare AstraZeneca plc (AZN) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Dollar Tree, Inc. — how do they compare? AstraZeneca plc trades at $158.09 (market cap $248.14B), while Dollar Tree, Inc. trades at $128.74 (market cap $24.61B). The key difference: AstraZeneca plc is far larger — about 10.1× Dollar Tree, Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals.
| AZN | DLTR | |
|---|---|---|
Market Cap | $248.14B | $24.61B |
Sector | Health | Health |
52-Week High | $209.48 | $141.21 |
52-Week Low | $147.06 | $85.04 |
Enterprise Value | $275.41B | $31.20B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Dollar Tree (DLTR) trades at $128.85, down 0.4% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue for 2025 was $17.58 billion, but net income showed a loss of $3.03 billion due to tax impacts, while operating cash flow improved to $2.86 billion. A $2.5 billion share repurchase authorization was announced in July 2026, signaling confidence.
The outlook is mixed: analyst consensus is a Buy with a $126.69 price target, near the current price, but risks include margin pressures from tariffs and volatile profitability. Upside potential exists from cost controls and consumer demand for value, yet investors should monitor Q2 earnings and competitive dynamics closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
